CHARACTERISTICS AND PREDICTIVE FACTORS OF REGIONAL LYMPH NODE METASTASIS IN FIGO I-III OVARIAN CANCER AT VIETNAM NATIONAL CANCER HOSPITAL

Pham Tuan Anh1,2, Truong Van Hop1,2, Tran Viet Hoang1, Pham Van Quan1, Pham Thi Dieu Ha1, Le Tri Chinh1, Nguyen Thi Phuong Anh1, Nguyen Thi Thanh Huyen3
1 Vietnam National Cancer Hospital
2 Ha Noi Medical University
3 Vinmec Times City International Hospital

Main Article Content

Abstract

Objective: to describe the characteristics of regional lymph node metastasis in ovarian cancer stages I-III and evaluate potential predictive factors for lymphatic spread in these cases.


Materials and Methods: A perspective and prospective study comprises 62 patients diagnosed with ovarian cancer, initially treated with cytoreductive surgery from January 2023 to August 2024 at the Department of Gynecological Surgery, National Cancer Hospital.


Results: The most common age group is 40-60 years (67.7 %). The avarage age at the time of diagnosis is 53.2±11.3 years. The majority of cases had High-grade Serous Carcinoma (HGSC) (62.9%). Preoperative MRI imaging characteristics: the detection rate of regional lymph nodes is 12.9%, with 75.0% of these nodes having a diameter ≥10mm. The proportion of disease stages II and III post-surgery (17.7% and 61.3%). The overall regional lymph node metastasis rates is 40.3%.,High-grade serous carcinoma has the highest rate of lymph node metastasis (80%). The test determines the cut-off level for lymph node size on CT/MRI to be 10mm, with a sensitivity of 80% and specificity of 67%. The lymph node metastasis rate in stage III is 43.8%, and in stage I, it is 40.7%. There were no patients with lymph node metastasis in stage II. The difference is not statistically significant (p > 0.05).


Conclusion: In early-stage disease, thorough lymph node assessment is essential for precise staging, often necessitating systemic lymphadenectomy based on imaging diagnostics and intraoperative evaluation of visible lesions. For advanced stages, selective lymph node excision is advised on a case-by-case basis to achieve optimal surgical outcomes.

Article Details

References

[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. May 2021;71(3):209-249.
[2] Observatory GC. Available at: https://gco.iarc.who.int/media/globocan/factsheets/cancers/25-ovary-fact-sheet.pdf (Accessed on February 28, 2024).
[3] Cancer today G. Statistics at a glance, Vietnam fact sheet. 2022.
[4] http://seer.cancer.gov/statfacts/html/ovary.html (Accessed on June 28, 2020).
[5] Koulouris CR, Penson RT. Ovarian stromal and germ cell tumors. Seminars in oncology. Apr 2009;36(2):126-136.
[6] Krasner C, Duska L. Management of women with newly diagnosed ovarian cancer. Seminars in oncology. Apr 2009;36(2):91-105.
[7] Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF. Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecologic oncology. Dec 2011;123(3):610-614.
[8] Timmers PJ, Zwinderman K, Coens C, Vergote I, Trimbos JB. Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. Oct 2010;20(7):1142-1147.
[9] Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet. Oncology. Nov 2006;7(11):925-934.